A study to compare safety and efficacy of intralesional injection of enalapril versus triamcinolone acetonide in the treatment of keloids

A comparative interventional study to assess the safety and efficacy of intralesional enalapril versus intralesional triamcinolone acetonide in the treatment of keloids among patients aged 18-60 years - NIL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/110971

Enrollment

Registered

2026-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L910- Hypertrophic scar

Interventions

Intervention1: Intralesional Enalapril: Intralesional enalapril will be administered at a concentration of 0.125mg per ml using an insulin syringe. Injection will be given into the keloid at one centi

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged 18-60 years with clinically diagnosed keloids 2.Patients having two or more keloids 3.Patients willing to participate and provide written informed consent

Exclusion criteria

Exclusion criteria: 1.Patients with hypotension 2.Patients with known hypersensitivity/allergy to ACE inhibitors or triamcinolone acetonide 3.Pregnant and lactating women 4.Patients with renal impairment/kidney disease 5.Patients unwilling to participate or unable to provide informed consent

Design outcomes

Primary

Measure	Time frame
Change in Vancouver Scar Scale (VSS) score from baseline after treatment with intralesional enalapril versus intralesional triamcinolone acetonide in patients with keloidsTimepoint: At baseline, 4 weeks, 8 weeks, and 12 weeks after initiation of treatment	—

Secondary

Measure	Time frame
1. Reduction in scar height (mm) measured using ruler 2.Change in patient-reported symptoms (pain and pruritus) assessed using Visual analogue scale (VAS) 3.Incidence of treatment-related adverse effects (skin atrophy, hypopigmentation, telangiectasia , ulceration)Timepoint: 1. Baseline, 4 weeks, 8 weeks, and 12 weeks 2. Baseline, 4 weeks, 8 weeks, and 12 weeks 3.Throughtout treatment period and at 12 week assessment	—

Measure

Time frame

1. Reduction in scar height (mm) measured using ruler 2.Change in patient-reported symptoms (pain and pruritus) assessed using Visual analogue scale (VAS) 3.Incidence of treatment-related adverse effects (skin atrophy, hypopigmentation, telangiectasia , ulceration)Timepoint: 1. Baseline, 4 weeks, 8 weeks, and 12 weeks 2. Baseline, 4 weeks, 8 weeks, and 12 weeks 3.Throughtout treatment period and at 12 week assessment

—

Countries

India

Contacts

Public ContactDr Shruti Sachindra Hajare

KLE Academy of Higher Education and Research Deemed to be University, Belagavi

shivakumarkpatil@gmail.com9844512315

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026